Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Healthcare investors often choose between established stability and high-growth innovation. Determining whether Johnson & Johnson (NYSE:JNJ) or Vertex Pharmaceuticals (NASDAQ:VRTX) is the superior choice requires examining their financial health and long-term strategies. Johnson & Johnson is a diversified giant pivoting toward its most profitable medical technology and innovative medicine segments. Vertex Pharmaceuticals is a specialized biotechnology leader that is successfully diversifying its pipeline beyond its core treatments. Both companies provide unique advantages for investors looking toward 2027. As a giant among healthcare stocks , the company focuses on its Innovative Medicine and MedTech segments to drive global growth. It distributes medications and devices to retailers, wholesalers, and hospitals, with a strategy centered on oncology, immunology, and neuroscience. Notable collaborations include an exclusive license for Darzalex from Genmab A/S (NASDAQ:GMAB) and a partnership with AbbVie (NYSE:ABBV) to co-commercialize the cancer drug Imbruvica. Continue reading